Pulido-Valdeolivas, Irene
Andorrà, Magí
Gómez-Andrés, David
Nakamura, Kunio
Alba-Arbalat, Salut
Lampert, Erika J.
Zubizarreta, Irati
Llufriu, Sara
Martinez-Heras, Eloy
Solana, Elisabeth
Sola-Valls, Nuria
Sepulveda, María
Tercero-Uribe, Ana
Blanco, Yolanda
Camos-Carreras, Anna
Sanchez-Dalmau, Bernardo
Villoslada, Pablo
Saiz, Albert
Martinez-Lapiscina, Elena H.
Funding for this research was provided by:
This study was supported by the Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168, PI15/0061, JR16/00006, FI16/00168)
Article History
Received: 2 November 2019
Accepted: 16 June 2020
First Online: 7 August 2020
Competing interests
: Dr Pulido-Valdeolivas has received travel reimbursement from Roche Spain, Novartis and Genzyme-Sanofi for international and national meetings over the past 3 years; she holds a patent for an affordable eye tracking system to measure eye movement in neurological diseases and holds stock options in Aura Innovative Robotics. She has also received travel reimbursement from European Academy of Neurology and European Committee for Treatment and Research in Multiple Sclerosis. Mr Andorra received funding from the Instituto de Salud Carlos III (Spain) and Fondo Europeo de Desarrollo Regional (FEDER-FI16/00168), Predoctoral Grant for Health Research (PFIS). Dr Gómez-Andrés has received travel reimbursement from Biogen, PTC, Novartis, Roche and Shire, and speaker honoraria from PTC and Shire. He holds stock in Aura Innovative Robotics and a patent for an affordable eye tracking system to measure eye movement in neurological diseases. He also received travel reimbursement from the European Academy of Neurology. Dr Nakamura has received speaking honoraria from Sanofi Genzyme, consulting fees from NeuroRx Research and royalty fees for license from Biogen. Ms. Alba-Albarat has no disclosures to report. Ms. Lampert has no disclosures to report. Dr Zubizarreta received compensation for consulting services from Bayer-Schering, speaking honoraria from Teva and Genzyme and travel reimbursement from Genzyme, Biogen, Merck and Bayer-Schering for national and international meetings over the last 3 years. She received funding from the Instituto de Salud Carlos III (Spain). Dr. Llufriu has received speaker honoraria from Biogen Idec, Novartis, Teva, Genzyme and Merck, and research support from “Proyecto de Investigación en Salud” (FIS 2015-PI15/00587: S.L, A.S.; FIS 2018 – PI18/01030: S.L., A.S.), integrated in the Plan. Estatal de Investigación Científica y Técnica de Innovación I+D+I and co-funded by the Instituto de Salud Carlos III, subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER, “Otra manera de hacer Europa”), from the Red Española de Esclerosis Múltiple (REEM - RD16/0015/0003), from the Ayudas Merck de Investigación 2017 de la Fundación Merck Salud and from Proyecto Societat Catalana Neurologia 2017. Dr Martinez-Heras has no disclosures to report. Dr Solana has received travel reimbursement from Merck Serono and Teva. Dr Solá-Valls has received compensation for consulting services and speaker honoraria from Genzyme-Sanofi and Bayer-Schering, and funding from the Instituto de Salud Carlos III (Spain) and the Fondo Europeo de Desarrollo Regional (FEDER-FI16/00251), Predoctoral Grant for Health Research (PFIS). Dr Sepulveda received speaker honoraria from Genzyme and Biogen Idec. Dr Tercero-Uribe has no disclosures to report. Dr Blanco received speaker honoraria from Biogen Idec, Novartis and Genzyme-Sanofi. Dr Camos-Carreras has no disclosures to report. Dr Sánchez-Dalmau has no disclosures to report. Dr Villoslada holds stocks or stock options and has received consultancy fees from Bionure Farma SL, Health Engineering SL, QMenta Inc and Spiral Therapeutics Inc. Dr Saiz has received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis, and research support from “Proyecto de Investigación en Salud” (FIS 2015 - PI15/00587: S.L, A.S.) integrated into the Plan Estatal de Investigación Científica y Técnica de Innovación 2013-2016 and co-funded by the Instituto de Salud Carlos III, sub-dirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER, “Otra manera de hacer Europa”), and from the Red Española de Esclerosis Múltiple (REEM-RD16/0015/0002). E.H. Martinez-Lapiscina is employed by the European Medicines Agency (Human Medicines Evaluation) since 16 April 2019. This article is related with her activity when affiliated to the Hospital Clinic of Barcelona and consequently, as external activity, it does not represent the views of the Agency or its Committees. Over the last three years and before enrolling EMA, she was granted funds from IDIBAPS and the Clinic of the University of Barcelona Foundation for research and educational purposes, and from the Instituto de Salud Carlos III (Spain) & Fondo Europeo de Desarrollo Regional (JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003, a grant for MS Innovation GMSI, 2016), the Fundació Privada Cellex, the Marató TV3 Charitable Foundation (20142030), Sanofi-Genzyme and Novartis. Over the last three years and before joining the EMA, she received travel support for international and national meetings from Roche and Sanofi-Genzyme, and in the past 3 years she also received honoraria for consultancies from Novartis, Roche and Sanofi. She is a member of the International Multiple Sclerosis Visual System (IMSVISUAL) Consortium.